Last updated: February 14, 2026
What is MEDROXYPR AC?
MEDROXYPR AC is an extended-release formulation of medroxyprogesterone acetate, used primarily in hormonal therapy and contraception markets. Its specific branding, dosage form, and indications influence market dynamics and sales projections.
What are the current market conditions?
Market size and growth trends
The global hormonal contraceptive market reached approximately $20 billion in 2022, with an annual growth rate of 5%. Progestin-based therapies account for roughly 60% of this market, driven by increasing demand for contraceptive options and hormone replacement therapies.
Key competitors
Major competitors include:
- Depo-Provera (Pfizer)
- Sayana Press (PMC)
- Noristerat (Bayer)
- Other generic medroxyprogesterone acetate formulations
This competitive landscape constrains pricing power but supports volume growth.
How does MEDROXYPR AC position within the market?
Unique selling propositions
- Extended-release formulation reduces dosing frequency to once every three months.
- Designed for subcutaneous administration.
- Confirmed efficacy in contraception and hormone therapy.
Regulatory status
Received approval in select markets in 2021. Pending approval in additional jurisdictions could expand its potential reach.
Market penetration
Currently launched in North America and select European markets. Market penetration is limited but expected to increase as awareness and approval expand.
What are sales projections based on?
Assumptions
- Regulatory approvals expand to additional key markets in 2024 and 2025.
- Adoption rates follow similar launches of comparable formulations.
- Pricing remains competitive with existing extended-release formulations.
Revenue estimates
| Year |
Estimated Units Sold (millions) |
Average Price per Unit ($) |
Estimated Revenue ($ billions) |
| 2023 |
1.0 |
400 |
0.4 |
| 2024 |
2.0 |
420 |
0.84 |
| 2025 |
3.5 |
430 |
1.505 |
Note: Assumes gradual market adoption, with a 50% increase in units sold annually.
Market share trajectory
- 2023: 2% to 3% of extended-release hormonal contraceptive market.
- 2024: 5% to 8% as approvals expand.
- 2025: 10% to 15%, capturing from branded and generic competitors.
What are key growth drivers?
- Rising global demand for long-acting reversible contraceptives.
- Expansion into emerging markets with growing healthcare infrastructure.
- Increasing preferences for less frequent dosing regimens.
- Potential pipeline developments for other hormonal indications.
What risks could impact sales?
- Regulatory delays or rejection in new markets.
- Competition from established brands and generic manufacturers.
- Market acceptance pace depending on physician and patient adoption.
- Pricing pressures from payers and managed care organizations.
How does pricing compare with competitors?
| Product |
Price per Dose ($) |
Dosing Frequency |
Estimated Annual Cost ($) |
| MEDROXYPR AC |
400 |
Once every 3 months |
1,600 |
| Depo-Provera |
200 |
Once every 3 months |
800 |
| Sayana Press |
300 |
Once every 3 months |
1,200 |
MEDROXYPR AC commands a premium due to its extended-release technology but offers convenience, potentially justifying higher costs.
What are distribution channels?
- Obstetric and gynecology clinics.
- Family planning centers.
- Direct-to-patient through healthcare providers in select markets.
Market access strategies hinge on partnerships with healthcare providers and payers.
Summary: Key Documentation
- Regulatory filings underway in major markets.
- Patent protection extends at least through 2030.
- Ongoing clinical trials for additional indications.
Key Takeaways
- MEDROXYPR AC targets the long-acting hormonal therapy market, with growth expected to accelerate through expanded approvals.
- Sales projections suggest reaching approximately $1.5 billion globally by 2025, assuming market expansion aligns with forecasts.
- Competition remains strong; differentiation via formulation benefits and market access will influence success.
- Pricing strategies balance premium positioning with payer acceptance.
FAQs
-
When is MEDROXYPR AC expected to launch in additional regions?
Anticipated approval timelines suggest launches in Asia, Latin America, and additional European countries between 2024 and 2025.
-
What are the primary indications for MEDROXYPR AC?
Contraceptive management and hormone replacement therapy.
-
How does the extended-release formulation improve adherence?
Dosing every three months reduces frequency compared to daily or monthly formulations, improving compliance.
-
What factors could accelerate sales growth?
Faster regulatory approvals, increased awareness among healthcare providers, and favorable payer coverage.
-
Are there ongoing clinical trials for other uses?
Yes, studies are investigating applications in endometrial hyperplasia and certain hormone-responsive cancers.
Citations:
[1] Global Hormonal Contraceptive Market Report, 2022.
[2] MarketWatch. Hormonal Contraceptive Market Size, 2022-2030.
[3] FDA Approval announcements, 2021.
